Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3062]
News [6213]
Articles [124]
Editorials [18]
Conferences [183]
elearning [32]
The RxPONDER trial and its impact on best clinical practice
Prof Christos Markopoulos and Prof Giuseppe Curigliano
The RxPONDER trial and its impact on best clinical practice ( Prof Christos Markopoulos and Prof Giuseppe Curigliano )
17 Dec 2021
WHO and St. Jude Children’s research hospital to dramatically increase global...
Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer...
WHO and St. Jude Children’s research hospital to dramatically increase global access to childhood cancer medicine ( Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer Initiative )
17 Dec 2021
The global platform for access to childhood cancer medicines
Dr James Downing - St. Jude Children’s Research Hospital, Memphis, USA
The global platform for access to childhood cancer medicines ( Dr James Downing - St. Jude Children’s Research Hospital, Memphis, USA )
17 Dec 2021
Cancer medicine shortages for children around the world
Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis...
Cancer medicine shortages for children around the world ( Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis, USA )
17 Dec 2021
OncoAlert and ecancer round up: SABCS 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer round up: SABCS 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
16 Dec 2021
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with...
Prof Meral Beksac and Prof Roman Hájek
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma ( Prof Meral Beksac and Prof Roman Hájek )
15 Dec 2021
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first...
Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients ( Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )
14 Dec 2021
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for...
Dr Michael Bishop - University of Chicago, Chicago, USA
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )
14 Dec 2021
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
13 Dec 2021
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail...
Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma. ( Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy )
11 Dec 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation